The chronic efficacy of midazolam.
The chronic efficacy of midazolam 15.0 mg was studied in 2 male and 10 female subjects. Only subjects with a complaint of sleep latency insomnia which was verified by polysomnography were included in the study. Following a screening and adaptation period, subjects spent 3 consecutive nights in the laboratory during the weeks of the study. Placebo was administered 15 min before lights out on the initial 8 and final 2 nights, and midazolam for the intervening 35 nights. Midazolam significantly reduced sleep latency parameters and significantly increased total sleep time the entire 5 weeks of nightly administration. No within-night rebound insomnia, residual daytime effects, or rebound effects upon discontinuation appeared.
Lamphere
J
J
Sleep Disorders and Research Center, Henry Ford Hospital, Detroit, Michigan 48202.
Roehrs
T
T
Vogel
G
G
Koshorek
G
G
Fortier
J
J
Roth
T
T
D000328:Adult; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008874:Midazolam / Q000627:therapeutic use*; D009483:Neuropsychological Tests; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D012894:Sleep Stages / Q000187:drug effects; D013997:Time Factors
D008874:Midazolam